LI
KNSA icon

Leap Investments’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Leap Investments’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$214K Sell
8,400
-2,900
-26% -$60.6K 0.14% 281
2020
Q1 		$175K Sell
11,300
-5,932
-34% -$92.8K 0.26% 176
2019
Q4 		$191K Buy
+17,232
New +$150K 0.09% 328

Other funds holding KNSA

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Leap Investments's KNSA Position: Q2 2020 in Review

Leap Investments reduced its Kiniksa Pharmaceuticals (KNSA) stake by 26% in Q2 2020, selling an estimated $60.6K and leaving 8,400 shares worth $214K. The position accounts for 0.14% of the portfolio, ranked #281.

Leap Investments first reported a position in KNSA in Q4 2019 and has held it in 3 quarters since. 96 funds tracked by Wall St. Rank hold KNSA as of Q2 2020.

  • Leap Investments held 8,400 shares of Kiniksa Pharmaceuticals worth $214K as of Q2 2020.
  • Leap Investments sold 2,900 Kiniksa Pharmaceuticals shares in Q2 2020, an estimated $60.6K.
  • Kiniksa Pharmaceuticals made up 0.14% of Leap Investments's portfolio in Q2 2020, its #281 holding.
  • Leap Investments first reported a position in Kiniksa Pharmaceuticals in Q4 2019 and has held it in 3 quarters since.
  • 96 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2020.

Based on Leap Investments's 13F filing for Q2 2020, filed 3 Aug 2020.